Literature DB >> 19478483

Long-term statin therapy and CSF cholesterol levels: implications for Alzheimer's disease.

Barbara A Evans1, James E Evans, Stephen P Baker, Kevin Kane, Joan Swearer, Douglas Hinerfeld, Richard Caselli, Ekaterina Rogaeva, Peter St George-Hyslop, Majaz Moonis, Daniel A Pollen.   

Abstract

BACKGROUND/AIMS: It is not yet established whether statins (lipophilic or hydrophilic) reduce the risk of Alzheimer's disease and, if so, by differentially modifying brain lipid levels. Our aim was to assess changes in brain cholesterol metabolism as reflected in the cerebrospinal fluid (CSF) before and after treatment with either atorvastatin or simvastatin.
METHODS: We carried out a longitudinal analysis of CSF cholesterol, lathosterol and 24(S)-hydroxycholesterol before and after treatment with maximum doses of statins in 10 asymptomatic subjects, 8 of whom were heterozygous for apolipoprotein E epsilon4, and in 6 presymptomatic PS1 subjects.
RESULTS: Statins initially reduced CSF lathosterol cholesterol and 24(S)-hydroxycholesterol in both PS1 and non-PS1 subjects reaching a nadir at 6-7 months, followed by a return to baseline at 15 months with an overshoot at 2 years, tending to return to baseline thereafter.
CONCLUSIONS: Possible long-term protective effects of statins are not likely largely related to the temporally-dependent biphasic effects of statin therapy upon the magnitude and direction of changes in CSF lipid levels and their subsequent return to baseline levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19478483     DOI: 10.1159/000221835

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  13 in total

1.  Statins and memory loss: An Australian experience.

Authors:  Anna I Jamolowicz; Huei-Yang Chen; Peter K Panegyres
Journal:  Australas Med J       Date:  2015-03-31

2.  Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders.

Authors:  D Allan Butterfield; Eugenio Barone; Cesare Mancuso
Journal:  Pharmacol Res       Date:  2011-04-22       Impact factor: 7.658

3.  Modulation of cholesterol in midlife affords cognitive advantage during ageing - a role for altered redox balance.

Authors:  M Cristina Polidori; Ludger Pientka; Gereon Nelles; Helen R Griffiths
Journal:  Int J Clin Exp Med       Date:  2010-04-20

Review 4.  Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

Authors:  Marco Tuccori; Sabrina Montagnani; Stefania Mantarro; Alice Capogrosso-Sansone; Elisa Ruggiero; Alessandra Saporiti; Luca Antonioli; Matteo Fornai; Corrado Blandizzi
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

5.  Does Cognitive Dysfunction after Carotid Endarterectomy Vary by Statin Type or Dose?

Authors:  Eric J Heyer; Joanna L Mergeche; Samuel S Bruce; E Sander Connolly
Journal:  Int J Brain Cogn Sci       Date:  2013

6.  Pathways of cholesterol homeostasis in mouse retina responsive to dietary and pharmacologic treatments.

Authors:  Wenchao Zheng; Natalia Mast; Aicha Saadane; Irina A Pikuleva
Journal:  J Lipid Res       Date:  2014-10-07       Impact factor: 5.922

7.  Prevention of Alzheimer's disease in high risk groups: statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein E epsilon 4.

Authors:  Daniel A Pollen; Stephen Baker; Douglas Hinerfeld; Joan Swearer; Barbara A Evans; James E Evans; Richard Caselli; Ekaterina Rogaeva; Peter St George-Hyslop; Majaz Moonis
Journal:  Alzheimers Res Ther       Date:  2010-10-29       Impact factor: 6.982

Review 8.  Inhibition of Inflammation Mediated Through the Tumor Necrosis Factor α Biochemical Pathway Can Lead to Favorable Outcomes in Alzheimer Disease.

Authors:  Daniah Shamim; Michael Laskowski
Journal:  J Cent Nerv Syst Dis       Date:  2017-07-28

9.  Cholesterol: its regulation and role in central nervous system disorders.

Authors:  Matthias Orth; Stefano Bellosta
Journal:  Cholesterol       Date:  2012-10-17

10.  Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's disease.

Authors:  Yuan-Yuan Zhang; Yu-Chen Fan; Min Wang; Dong Wang; Xiao-Hong Li
Journal:  Clin Interv Aging       Date:  2013-01-31       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.